Long-lasting Responses to Immunomodulatory Drugs (IMIDs) in Combination with Dexamethasone in Multiple Myeloma; Identification of Exceptional Responders at any Treatment Line

Journal Title: Haematology International Journal - Year 2017, Vol 1, Issue 2

Abstract

1.1. Background: There is a growing interest in the study of patients that achieve exceptionally long-lasting remissions although suffering from incurable neoplastic disorders. This is the case for multiple myeloma (MM), the treatment of which has greatly improved with the emergence of new, biology-driven modalities that prolonged survival. The identification of “exceptional responders” to basic treatment such as immunoregulatory drugs (IMIDs) and dexamethasone could eventually reveal a small proportion of patients potentially curable with more drugs combinations. 1.2. Aims: To investigate MM exceptional responders to IMiDs. 1.3. Objectives: To identify exceptional responders among all patients with symptomatic MM treated either at diagnosis or in relapse with an IMID (thalidomide, lenalidomide, pomalidomide) in combination with dexamethasone and to study their clinical characteristics and survival. 1.4. Materials and Methods: A cohort of 164 patients was studied. “Exceptional responders” were defined as patients that remained in remission for at least 72 months after 1st line treatment, 60 months after 2nd line, 42 months after 3rd to 6th line and for at least 30 months beyond 6th line. Statistical analysis was performed using the SPSS v.24.0 software. Survival was evaluated by the log rank test. 1.5. Results: Thirty-one (19%) exceptional responders were detected, of whom 11 (15%) out of 75 received thalidomide/dexamethasone (TD), 18 (14%) out of 132 lenalidomide/dexamethasone (LD) and 2 (25%) out of 8 pomalidomide dexamethasone (PD). The median number of treatment lines received prior to TD, LD and PD treatment was 2, 2 and 7 respectively. Exceptional responders’ survival from TD, LD and PD treatment to last follow-up or death was 85, 73 and 35 months while their overall survival was 95, 94,5 and 149 months respectively. Seventeen patients are alive and 4 disease-free. They did not exhibit specific clinical or biochemical profile beside the absence of hypercalcemia and extramedullary disease at treatment initiation. 1.6. Conclusion: We identified exceptional responders to IMIDs-based treatment, their further examination may enlighten on disease biologic aspects that could open the way to cure.

Authors and Affiliations

Marie-Christine Kyrtsonis

Keywords

Related Articles

Knowledge, Perception and Opinion of Health Workers on Bone Marrow Transplantation in Nigeria

1.1. Background: Bone marrow transplantation (BMT) or haematopoietic stem cell transplantation (HSCT) is a procedure used to cure haematopoietic malignancies, poorly functioning haematopoietic or immune system and geneti...

A Survey of Clinicians Practice Patterns in Anticoagulation Therapy & Prophylaxis in Nigeria

Introduction: Therapeutic and prophylactic anticoagulation is under-prescribed in Nigeria, Dismal practice patterns of anticoagulation, lack of hospital-based anticoagulation policy may be contributory Objective: The aim...

A Unique Case of Primary Hepatic CD30-Positive, CD15-Negative Classical Hodgkin’s Lymphoma Presenting as Fever of Unknown Origin and Acute Hepatic Failure

Hodgkin’s lymphoma is a B-cell lymphoproliferative neoplasm that commonly presents with lymphadenopathy and constitutional symptoms. Primary Hodgkin’s lymphoma of the liver without extrahepatic lymphadenopathy is rare, r...

Impairment of Micronucleus and DNA in the 2-Chloro-4-Ethylamino-6- Isopropylamino-1, 3, 5-Triazine Exposed Poecilia Sphenops

The micronucleus and DNA fragmentation assays have been used progressively more to evaluate genotoxicity of many compounds in contaminated aquatic atmosphere. The objective of the current study was to investigate the gen...

Platelet Hyperaggregation and Morphological Changes By Electron Microscopy in Simulated Dive

Dysbaric osteonecrosis and electroencephalogram (EEG) disturbances prompted the previous studies already submitted at Argentine Society of Haematology on the Scientific Meeting at 1982 and on the First Haemotherapy and I...

Download PDF file
  • EP ID EP291039
  • DOI -
  • Views 132
  • Downloads 0

How To Cite

Marie-Christine Kyrtsonis (2017). Long-lasting Responses to Immunomodulatory Drugs (IMIDs) in Combination with Dexamethasone in Multiple Myeloma; Identification of Exceptional Responders at any Treatment Line. Haematology International Journal, 1(2), 1-6. https://europub.co.uk/articles/-A-291039